02:18 , Jan 3, 2013 |  BC Extra  |  Financial News

Heart Metabolics closes series A tranche

Heart Metabolics Ltd. (London, U.K.) raised $4 million in the first tranche of a planned $6 million series A round. Trans Tasman Commercialization Fund led the tranche, with participation from AshHill Investments. Additionally, Heart Metabolics...
07:00 , Jun 11, 2012 |  BioCentury  |  Emerging Company Profile

Armetheon: Stopping the bleeding

Former ARYx Therapeutics Inc. President Peter Milner co-founded Armetheon Inc. to take a second shot at developing tecarfarin three years after the ARYx anticoagulant failed a Phase II/III trial to prevent blood clots. This time...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Company News

AshHill Pharmaceutical Investments LLC finance news

AshHill Pharmaceutical Investments LLC , Fort Thomas, Ky.   Business: Finance   AshHill closed $5 million for its AshHill PharmaFund I. The fund, which makes seed and early-stage investments, was targeting a $25 million close....
08:00 , Nov 21, 2011 |  BC Week In Review  |  Clinical News

Naronapride regulatory update

FDA's Gastrointestinal Drugs Advisory Committee voted 17-4 with 1 abstention against requiring companies to conduct a dedicated cardiovascular safety trial of serotonin (5-HT4) receptor agonists for GI indications. Of the 10 cardiologists on the panel,...
01:25 , Nov 18, 2011 |  BC Extra  |  Clinical News

GI panel: CV safety studies unnecessary

FDA's Gastrointestinal Drugs Advisory Committee on Thursday voted 17-4 with 1 abstention against requiring companies to conduct a dedicated cardiovascular safety trial of serotonin (5-HT4) receptor agonists for GI indications. Of the 10 cardiologists on...
01:42 , Nov 16, 2011 |  BC Extra  |  Company News

FDA posts 5-HT4 receptor agonist briefing documents

FDA posted briefing documents ahead of the agency's Gastrointestinal Drugs Advisory Committee meeting on Thursday to discuss cardiovascular safety programs for serotonin (5-HT4) receptor agonists in development for GI indications. FDA will ask the panel...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Company News

ARYx gastrointestinal, cardiovascular news

ARYx said it would wind down operations after FDA delayed for the second time to July a response to an SPA submitted for a Phase III trial of naronapride ( ATI-7505 ) to treat gastrointestinal...
08:00 , Jan 3, 2011 |  BioCentury  |  Finance

Trickle-down effect

Although companies in the $1-$1.9 billion market cap range were the big winners for 2010 with a 28% gain, last quarter saw gains migrate into lower rungs of the market cap ladder. Small caps with...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Company News

ARYx gastrointestinal, cardiovascular news

ARYx terminated all of its employees, including officers, after FDA delayed to 1Q11 a response to an SPA submitted for naronapride ( ATI-7505 ). ARYx said it was not able to obtain financing to continue...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Financial News

ARYx financial update

ARYx received a letter from NASDAQ indicating that the company has not regained compliance with the minimum $50 million market value requirement for continued listing. The company plans to request a hearing. ARYx Therapeutics Inc....